JCR Pharmaceuticals Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the full year, the company expected net sales of JPY 41,300 million, operating profit of JPY 5,400 million, profit attributable to owners of parent of JPY 3,700 million and basic earnings per share of JPY 29.65.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
594 JPY | -1.98% |
|
+2.06% | -49.23% |
06-24 | JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from S&P Japan 500 | CI |
05-31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.23% | 461M | |
+55.19% | 801B | |
+47.26% | 631B | |
-6.09% | 359B | |
+21.92% | 337B | |
+18.40% | 245B | |
+3.64% | 231B | |
+12.98% | 219B | |
+10.86% | 171B | |
-2.78% | 161B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025